MedPath

Tagged News

Medicines Discovery Catapult and Crown Bioscience Form Strategic Alliance to Accelerate Radiopharmaceutical Development

OncologyPrecision MedicineDrug Discovery
  • Medicines Discovery Catapult and Crown Bioscience have established a strategic global collaboration to create an integrated translational biology platform for radiopharmaceutical development.
  • The partnership combines MDC's radiochemistry expertise and imaging technologies with Crown Bioscience's preclinical oncology capabilities to support companies across the radiopharmaceutical pipeline.
  • The collaboration aims to accelerate drug development by enabling rapid testing of radiopharmaceutical efficacy and safety while reducing clinical development risk.
  • Together, the organizations will deliver preclinical comparator studies with approved standards of care to support successful Investigational New Drug submissions.

Absci Partners with Oracle and AMD to Accelerate AI-Driven Drug Discovery Platform

AIDrug Discovery
  • Absci, a clinical-stage biotech company, announced a collaboration with Oracle Cloud Infrastructure and AMD to enhance its generative AI Drug Creation Platform for biologics design.
  • The partnership leverages Oracle's AI infrastructure and AMD's next-generation Instinct MI355X GPUs to accelerate molecular dynamics simulations and antibody design workflows.
  • The collaboration enables Absci to reduce inter-GPU latency to 2.5 microseconds and achieve terabytes-per-second throughput for large-scale model training and data streaming.
  • Absci's platform combines AI models with synthetic biology to create novel therapeutics through continuous feedback loops between algorithms and wet lab validation.

Beckman Coulter Life Sciences Partners with HSE•AG to Automate Nucleic Acid Quantification Workflows

Drug Discovery
  • Beckman Coulter Life Sciences has partnered with Swiss company HSE•AG to integrate automated nucleic acid quantification directly into liquid handling workflows using Biomek i-Series workstations.
  • The collaboration combines HSE's eviDense UV Photometer and eviFluor Duo fluorometer with Beckman's automation platforms to enable real-time measurements without manual intervention.
  • The integrated system can deliver fluorometric analysis results for 96 samples in as little as 20 minutes while maximizing walk-away time for extraction and NGS library preparation.
  • The partnership aims to accelerate drug discovery by reducing manual workloads and enhancing data reliability across genomic workflows through fully automated, end-to-end sample preparation solutions.

Scenic Biotech Appoints Dr. Roland W. Bürli as Chief Scientific Officer to Advance Modifier Therapy Pipeline

Drug Discovery
  • Scenic Biotech has appointed Dr. Roland W. Bürli as Chief Scientific Officer, effective September 1, 2025, to lead the development of first-in-class modifier therapies for neurodegenerative and metabolic diseases.
  • Dr. Bürli brings over 25 years of drug development experience and a proven track record of advancing preclinical programs through clinical evaluation, including his recent work at Cerevance where he advanced CVN293 through Phase 1 trials.
  • The appointment strengthens Scenic's ability to advance its innovative Cell-Seq platform-derived pipeline, which represents a novel approach to treating genetic disorders by targeting modifier genes rather than primary disease-causing mutations.
  • Scenic's modifier therapy approach has recently achieved scientific validation through two high-impact publications in Nature, positioning the company to make meaningful impacts in treating severe disorders.

LGC Group Opens $100 Million Organic Chemistry Synthesis Center in Canada to Expand Global Drug Discovery Support

Drug Discovery
  • LGC Group officially opened a CAD $100 million Organic Chemistry Synthesis Centre of Excellence in Vaughan, Ontario, creating one of the world's largest facilities of its kind at 203,000 square feet.
  • The facility significantly expands Toronto Research Chemicals' capacity to synthesize complex organic molecules that are critical building blocks for global drug discovery pipelines in pharmaceutical and biotechnology companies.
  • Products manufactured at the new center will be shipped to more than 170 countries, supporting research in cancer, infectious disease, mental health, and environmental safety applications.
  • The investment strengthens Canada's position as a global hub for life sciences innovation and manufacturing, with the facility enabling faster and more reliable delivery of specialized research chemicals to customers worldwide.

insitro and Eli Lilly Partner to Develop AI-Powered ADMET Prediction Models for Small Molecule Drug Discovery

Drug DiscoveryAI
  • insitro and Eli Lilly announced a collaboration to develop advanced machine learning models that can accurately predict key pharmacological properties of small molecules, including their behavior in vivo.
  • The partnership will leverage Lilly's proprietary preclinical data from decades of drug discovery programs to train AI models for predicting ADMET properties, potentially reducing development timelines and costs.
  • The models will be integrated into Lilly TuneLab, a new drug discovery platform designed to accelerate medicine development by providing biotechnology companies access to powerful machine learning tools.
  • Traditional approaches to optimizing pharmacokinetics can take years and cost tens of millions of dollars, making this AI-driven approach a potential game-changer for the industry.

Eli Lilly Launches TuneLab AI Platform to Democratize Drug Discovery for Biotech Companies

AIDrug Discovery
  • Eli Lilly has launched TuneLab, an AI/ML platform providing biotech companies access to drug discovery models trained on over $1 billion worth of proprietary research data.
  • The platform uses federated learning to allow smaller companies to access Lilly's AI capabilities without exposing proprietary data from either party.
  • TuneLab includes comprehensive datasets covering drug disposition, safety, and preclinical data from hundreds of thousands of unique molecules tested by Lilly.
  • The platform aims to address the fundamental challenge faced by early-stage biotechs that lack access to large-scale, high-quality data needed for effective AI model training.

Baylor College of Medicine Partners with Site Tx to Advance Immune-Targeted Small Molecule Drug Discovery

Drug Discovery
  • Baylor College of Medicine and Site Tx, Inc. have launched a multi-year collaboration to develop novel small-molecule drugs for fine-tuning immune responses across multiple diseases.
  • The partnership combines Baylor's DNA-encoded library of over 7 billion unique compounds with Site Tx's high-throughput functional genomics platform for precise immune modulation.
  • The first phase of research, focusing on screening a protein implicated in immune regulation, is currently underway with potential to unlock transformative therapies.

Rapafusyn Pharmaceuticals Secures $44 Million Series A to Advance Non-Degrading Molecular Glue Platform

Drug DiscoveryAI
  • Rapafusyn Pharmaceuticals closed an over-subscribed $44 million Series A financing round, adding BioTrack Capital and Yonjin Capital as new investors alongside existing backers.
  • The company's RapaGlue™ platform creates non-degrading molecular glues that can target previously undruggable proteins across oncology, immunology, renal and pain disease areas.
  • Rapafusyn's lead program, a selective ENT1 inhibitor for renal disease, is advancing toward IND-enabling studies after demonstrating compelling activity in disease models.
  • The platform leverages machine learning and AI methods with a DNA-encoded library of over 8 billion molecular glues to achieve industry-leading success rates in drug discovery.

Atelerix Partners with Rodon Global to Revolutionize Biomedical Cold-Chain Logistics with Cryo-Free Technology

Drug Discovery
  • Atelerix and Rodon Global have signed a memorandum of understanding to integrate cryo-free cell preservation technology into international freight services for drug discovery and clinical trials.
  • The partnership enables biological samples including whole blood, primary cells, and organoids to remain stable at ambient temperatures for up to two weeks without freezing.
  • Rodon will offer Atelerix's hypothermic preservation solutions across its expanding operations in the US, UK, South Africa, and Singapore.
  • The collaboration addresses critical supply chain challenges in transporting temperature-sensitive biomaterials while reducing energy costs and simplifying logistics protocols.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.